Welcome to the Therakos Institute

At the Therakos Institute, our primary goal is to advance knowledge and understanding around Extracorporeal Photopheresis (ECP) immunomodulation. We have forged valuable partnerships with leading experts from around the world, regularly bringing our best and brightest together to provide accessible education to HCPs. Through these collaborations, we aim to build a better future for patients.

Gain online access to our live and on-demand webinars.

Sign-up to the upcoming webinars to learn more about the ECP therapy and get the opportunity to watch any past webinars you didn’t have chance to attend.

Our Educational Offer

Webinars

Up-to-date coverage of a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

Explore Our Webinars

Symposia

Major thought leaders present on specific topics on the latest in ECP Immunomodulation – guaranteed to be both stimulating and informative.

Symposia

Ask the Expert

Private, one-to-one sessions with leading experts in their respective fields of relevance to ECP and its clinical applications.

Ask the Expert

Map of Europe with centres of excellence

Courses

We partner with several European centres of excellence (CoE) to provide high quality professional education to committed healthcare professionals.

Courses

Speaker meetings

The latest scientific knowledge and advancements in ECP brought to life in conversation by major thought leaders.

Speaker Meetings

Partnerships

Expanding the ECP Immunomodulation educational offering of the Therakos Institute.

Partnerships

EBMT 2024 Highlight Report

DISCOVER MORE

30 years of THERAKOS ECP Immunomodulation^TM treating GvHD

Discover More

Upcoming events

Developing leadership in healthcare

An SDA Bocconi course. Sponsored by Mallinckrodt.

Discover more

Brilliant Speakers

Our communication course dedicated to bringing our leaders into the new era of engagement.

Discover more

Clinicians looking at medical results on a tablet

Create your

account to access live webinars, member events and exclusive content.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Welcome to the Therakos Institute

Gain online access to our live and on-demand webinars.

Our Educational Offer

Webinars

Symposia

Ask the Expert

Courses

Speaker meetings

Partnerships

EBMT 2024 Highlight Report

30 years of THERAKOS ECP ImmunomodulationTM treating GvHD

Upcoming events

Developing leadership in healthcare

Brilliant Speakers

Welcome to the Home of ECP

You are leaving the Therakos.eu website.